Peyman Hadji

9.3k total citations · 2 hit papers
167 papers, 5.8k citations indexed

About

Peyman Hadji is a scholar working on Oncology, Genetics and Orthopedics and Sports Medicine. According to data from OpenAlex, Peyman Hadji has authored 167 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Oncology, 64 papers in Genetics and 52 papers in Orthopedics and Sports Medicine. Recurrent topics in Peyman Hadji's work include Bone health and treatments (93 papers), Estrogen and related hormone effects (58 papers) and Bone health and osteoporosis research (45 papers). Peyman Hadji is often cited by papers focused on Bone health and treatments (93 papers), Estrogen and related hormone effects (58 papers) and Bone health and osteoporosis research (45 papers). Peyman Hadji collaborates with scholars based in Germany, United States and United Kingdom. Peyman Hadji's co-authors include Robert E. Coleman, Matti Aapro, Jean‐Jacques Body, Matthias Kalder, Michael Gnant, Volker Ziller, Allan Lipton, Jørn Herrstedt, Ioannis Kyvernitakis and Lorenz C. Hofbauer and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

Peyman Hadji

155 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bone health in cancer patients: ESMO Clinical Practice Guidelines

2014 401 citations Robert E. Coleman, Jean‐Jacques Body et al. Annals of Oncology profile →
Bone health in cancer: ESMO Clinical Practice Guidelines

2020 294 citations Robert E. Coleman, Peyman Hadji et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Peyman Hadji

Since Specialization

Citations

This map shows the geographic impact of Peyman Hadji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peyman Hadji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peyman Hadji more than expected).

Fields of papers citing papers by Peyman Hadji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peyman Hadji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peyman Hadji. The network helps show where Peyman Hadji may publish in the future.

Co-authorship network of co-authors of Peyman Hadji

This figure shows the co-authorship network connecting the top 25 collaborators of Peyman Hadji. A scholar is included among the top collaborators of Peyman Hadji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peyman Hadji. Peyman Hadji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bone health in cancer: ESMO Clinical Practice Guidelines breakdown → 2020 ·Annals of Oncology ·Robert E. Coleman, Peyman Hadji, Jean‐Jacques Body, Daniele Santini, Edward Chow, Evangelos Terpos, Stéphane Oudard, Øyvind S. Bruland, Patrick Flamen, Andreas Kurth, Catherine Van Poznak, Matti Aapro, Karin Jordan	294
2	GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab 2016 ·Osteoporosis International ·Peyman Hadji, Ioannis Kyvernitakis, P. Kann, Christopher Niedhart, Lorenz C. Hofbauer, Hans‐Peter Schwarz, (unknown), Friederike Thomasius, Matthias Schulte, Michele Intorcia, (unknown), (unknown)	45
3	Bone health in the elderly cancer patient: A SIOG position paper 2016 ·Cancer Treatment Reviews ·Jean‐Jacques Body, Evangelos Terpos, Bertrand Tombal, Peyman Hadji, Ahmed A. Arif, Annie Young, Matti Aapro, Rob Coleman	33
4	Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study 2016 ·Annals of Oncology ·Yvonne Nestoriuc, Pia von Blanckenburg, (unknown), Arthur J. Barsky, Peyman Hadji, U.‐S. Albert, Winfried Rief	73
5	Evolution of subject characteristics in FREEDOM and its extension for up to 8 years 2015 ·Australasian Journal on Ageing ·J.D. Adachi, (unknown), (unknown), Peyman Hadji, Socrates E. Papapoulos, Christopher Recknor, Paula Dakin, (unknown), (unknown)	2
6	Discontinuation rates of menopausal hormone therapy among postmenopausal women in the post-WHI study era 2015 ·Climacteric ·Ioannis Kyvernitakis, Karel Kostev, O. Hars, (unknown), Peyman Hadji	11
7	Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network 2015 ·Geburtshilfe und Frauenheilkunde ·Peter A. Fasching, Sara Y. Brucker, Tanja Fehm, Friedrich Overkamp, Wolfgang Janni, Markus Wallwiener, Peyman Hadji, Erik Belleville, Lothar Häberle, Florin‐Andrei Taran, Diana Lüftner, Michael P. Lux, Johannes Ettl, Volkmar Müller, Hans Tesch, D. Wallwiener, Andreas Schneeweiß	43
8	Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer 2014 ·Journal of Cancer Research and Clinical Oncology ·Ioannis Kyvernitakis, Tilman D. Rachner, Anja Urbschat, O. Hars, Lorenz C. Hofbauer, Peyman Hadji	26
9	Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study 2014 ·Breast Cancer Research and Treatment ·Peyman Hadji, (unknown), M. Ziller, Katrin Birkholz, Monika Baier, Mathias Muth, Peter Herbert Kann	12
10	Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2 2013 ·JNCI Journal of the National Cancer Institute ·Michael Gnant, José Baselga, Hope S. Rugo, Shinzaburo Noguchi, Howard A. Burris, Martine Piccart, Gabriel N. Hortobágyi, Janice F. Eakle, Hirofumi Mukai, Hiroji Iwata, Matthias Geberth, Lowell L. Hart, Peyman Hadji, Mona El-Hashimy, (unknown), Tetiana Taran, Tarek Sahmoud, David Lebwohl, Mario Campone, Kathleen I. Pritchard	77
11	Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis 2013 ·Breast Cancer Research and Treatment ·Peyman Hadji, Volker Ziller, Ioannis Kyvernitakis, Michael Bauer, (unknown), Nina Schmidt, Karel Kostev	73
12	Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor–Positive Breast Cancer 2012 ·Obstetrical & Gynecological Survey ·W. van de Water, Christos Markopoulos, Cornelis J.�H. van de Velde, Caroline Seynaeve, Annette Hasenburg, Daniel Rea, Hein Putter, J.W.R. Nortier, Anton J.M. de Craen, E.T.M. Hille, Esther Bastiaannet, Peyman Hadji, Rudi G. J. Westendorp, Gerrit‐Jan Liefers, Stephen E. Jones	21
13	PCN106 Persistence in Patients With Breast Cancer Treated With Tamoxifen or Aromatase Inhibitors: Results of a Retrospective Cohort Study 2012 ·Value in Health ·Karel Kostev, (unknown), Peyman Hadji	1
14	Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial 2011 ·The Lancet ·Cornelis JH van de Velde, Daniel Rea, Caroline Seynaeve, Hein Putter, Annette Hasenburg, Jean-Michel Vannetzel, Robert Paridaens, Christos Markopoulos, Yasuo Hozumi, E.T.M. Hille, D. G. Kieback, Lina Asmar, Jan Smeets, J.W.R. Nortier, Peyman Hadji, John M.S. Bartlett, Stephen E. Jones	264
15	Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer 2009 ·Annals of Oncology ·Volker Ziller, Matthias Kalder, Ute‐Susann Albert, (unknown), M. Ziller, Uwe Wagner, Peyman Hadji	220
16	The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer 2009 ·European Journal of Cancer ·Peyman Hadji, M. Ziller, (unknown), (unknown), Matthias Kalder	65
17	Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial 2008 ·Journal of Bone and Mineral Research ·Jacques P. Brown, Richard L. Prince, Chad Deal, Robert R. Recker, Douglas P. Kiel, (unknown), Peyman Hadji, Lorenz C. Hofbauer, José María Álvaro‐Gracia, Huei Wang, Matthew Austin, Rachel B. Wagman, Richard Newmark, Cesar Libanati, Javier San Martín, Henry G. Bone	436
18	Monthly ibandronate improves persistence vs. weekly bisphosphonates after 9 months of treatment 2007 ·Osteoporosis International ·Peyman Hadji, (unknown), Carolyn Harley, (unknown), Charles E. Barr, Sara Poston, Cyrus Cooper	1
19	Sonographische Variabilität laktierender Adenome am Beispiel von 4 langzeitüberwachten Fällen 2001 ·Ultraschall in der Medizin - European Journal of Ultrasound ·Karin Bock, Volker Duda, Peyman Hadji, (unknown), Annette Ramaswamy, Stephan Schmidt, (unknown)	3
20	The influence of menopause and body mass index on serum leptin concentrations 2000 ·European Journal of Endocrinology ·Peyman Hadji, O. Hars, Karin Bock, Gabriel Sturm, Thomas Bauer, G. Emons, (unknown)	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact